美迪西(688202.SH):已與多家AI製藥企業達成戰略合作
格隆匯3月15日丨美迪西(688202.SH)在投資者互動平台表示,公司會積極應對行業和市場環境的變化,一如既往深耕主營業務,持續優化經營,加大國內外市場拓展力度,提升項目實施及項目交付的效率,確保經營有序進行。公司會持續夯實臨牀前一體化綜合研發服務能力,並且在業務規模擴大的同時,積極推進各項提質增效措施,提升運營效率和盈利能力。公司一直高度關注AI技術的發展趨勢,已與多家AI製藥企業達成戰略合作,充分整合外部技術資源和內部研發能力,實現雙向賦能。公司將結合自身業務,繼續積極探索相關技術在研發業務中的應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.